(Q28166489)

1

0 references

Grigoris Gerotziafas

2

0 references

Françoise Robert

3

0 references

Chantal Lecrubier

4

0 references

Meyer Michel Samama

5

0 references

Mohamed Hatmi

6

0 references

Ismail Elalamy

British Journal of Haematology

7

0 references

language of work or name

English

0 references

publication date

January 2004

0 references

published in

0 references

volume

124

0 references

issue

1

0 references

page(s)

80-5

0 references

cites work

Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04727.X

Low-grade exercise enhances platelet aggregability in patients with obstructive coronary disease independently of myocardial ischemia

21 April 2017

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04727.X

Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease

21 April 2017

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04727.X

Clinical application of the PFA-100

21 April 2017

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04727.X

Profile and prevalence of aspirin resistance in patients with cardiovascular disease

21 April 2017

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04727.X

A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease

21 April 2017

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04727.X

Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate

21 April 2017

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04727.X

Effect of aspirin treatment in patients with peripheral arterial disease monitored with the platelet function analyzer PFA-100

21 April 2017

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04727.X

Rational use of the PFA-100 device for screening of platelet function disorders and von Willebrand disease.

21 April 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04727.X

Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04727.X

A comparison of the effects of aspirin on bleeding time measured using the Simplate method and closure time measured using the PFA-100, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04727.X

Influence of ABO blood groups on primary hemostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04727.X

Platelet-active drugs : the relationships among dose, effectiveness, and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04727.X

Comparison of in vitro closure time (PFA-100) with whole blood electrical aggregometry and platelet surface antigen expression in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04727.X

Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of eryt

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04727.X

Ultrastructural analysis of the distribution of von Willebrand factor and fibrinogen in platelet aggregates formed in the PFA-100

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04727.X